Herrera Maurice
Known title: Chief Marketing OfficerCIK: 0001891927
Associated companies
Transaction History
| CVSA | ▼ Sell | Tax Withholding | 343 | $33K | 11/13/2025 | View on chart |
| CVSA | ▲ Buy | Grant | 1,750 | $170K | 11/12/2025 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 734 | $99K | 8/24/2025 | View on chart |
| CVSA | ▲ Buy | Grant | 8,752 | $1.2M | 8/24/2025 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 4,478 | $604K | 8/24/2025 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 4,979 | $672K | 8/23/2025 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 880 | $119K | 8/23/2025 | View on chart |
| CVSA | ▲ Buy | Grant | 9,757 | $1.3M | 8/23/2025 | View on chart |
| CVSA | ▲ Buy | Grant | 2,010 | $181K | 11/13/2024 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 5,021 | $458K | 11/10/2024 | View on chart |
| CVSA | ▼ Sell | Open Market | 8,165 | $576K | 9/11/2024 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 739 | $56K | 8/24/2024 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 865 | $65K | 8/23/2024 | View on chart |
| CVSA | ▼ Sell | Open Market | 4,200 | $252K | 12/8/2023 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 3,532 | $196K | 11/10/2023 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 515 | $22K | 8/24/2023 | View on chart |
| CVSA | ▲ Buy | Grant | 5,160 | $222K | 8/23/2023 | View on chart |
| CVSA | ▼ Sell | Open Market | 2,800 | $103K | 12/15/2022 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 3,524 | $151K | 11/10/2022 | View on chart |
| CVSA | ▲ Buy | Grant | 4,380 | $174K | 8/24/2022 | View on chart |
| CVSA | ▲ Buy | Grant | 29,550 | $1000K | 11/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Covista receives mixed analyst coverage and rating update
Recent commentary on Covista is mixed. ChartMill describes the stock as a GARP case with reasonable growth and valuation. Yahoo published both a target‑focused piece and a separate article highlighting reasons to avoid the stock. BMO Capital kept an Outperform rating but lowered its price target to $145.
Covista receives mixed analyst coverage and rating update. Recent commentary on Covista is mixed. ChartMill describes the stock as a GARP case with reasonable growth and valuation. Yahoo published both a target‑focused piece and a separate article highlighting reasons to avoid the stock. BMO Capital kept an Outperform rating but lowered its price target to $145.